Metsera, Inc. (MTSR)

NASDAQ: MTSR · Real-Time Price · USD
52.84
-0.06 (-0.11%)
At close: Oct 8, 2025, 4:00 PM EDT
52.77
-0.07 (-0.13%)
After-hours: Oct 8, 2025, 7:58 PM EDT
-0.11%
Market Cap5.56B
Revenue (ttm)n/a
Net Income (ttm)-307.82M
Shares Out 105.28M
EPS (ttm)-5.89
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,981,636
Open52.77
Previous Close52.90
Day's Range52.62 - 53.20
52-Week Range12.30 - 54.47
Betan/a
AnalystsStrong Buy
Price Target58.00 (+9.77%)
Earnings DateNov 26, 2025

About MTSR

Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity, as well as MET-815i to reduce weight or prevents weight gain. The company was incorporated in 2022 and is based in New York, New York. [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jan 31, 2025
Employees 81
Stock Exchange NASDAQ
Ticker Symbol MTSR
Full Company Profile

Financial Performance

Financial Statements

Analyst Summary

According to 7 analysts, the average rating for MTSR stock is "Strong Buy." The 12-month stock price target is $58.0, which is an increase of 9.77% from the latest price.

Price Target
$58.0
(9.77% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Healthy Returns: Pfizer's new obesity bet, Metsera, releases encouraging data on lead drug

Metsera released data from mid-stage trials on its lead obesity drug candidate, while a high stakes Medicare open enrollment approaches.

Other symbols: PFE
8 days ago - CNBC

Metsera Posts Promising Weight-Loss Drug Results. It Could Be a Win for Pfizer.

Pfizer said last week it would pay $47.50 per share for Metsera, and an extra $22.50 per share if its drugs hit certain milestones.

Other symbols: PFE
8 days ago - Barrons

Metsera's obesity drug shows promising weight loss in mid-stage trials

Metsera said on Monday that its experimental obesity drug showed significant weight loss and favorable tolerability in mid-stage studies.

9 days ago - Reuters

Metsera Reports Positive Phase 2b Results for First- and Best-in-Class Ultra-long Acting GLP-1 RA Candidate MET-097i, Enabling Rapid Transition into Phase 3

Placebo-subtracted mean weight loss up to 14.1% after 28 weeks with no plateau Potential for best-in-class tolerability with minimal diarrhea signal, 13% nausea, and 11% vomiting High study and treatm...

9 days ago - GlobeNewsWire

METSERA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Metsera, Inc. - MTSR

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale Met...

Other symbols: PFE
15 days ago - Business Wire

Pfizer bets $7.3 billion on obesity drugs with Metsera buy

Pfizer is fattening its drug portfolio by betting that more people will want to slim down. The New York drugmaker announced Monday that it's acquiring Metsera, and its portfolio of four medications fo...

Other symbols: PFE
16 days ago - Fast Company

BMO's Seigerman on Pfizer-Metsera deal: Bullish as we've waited on Pfizer's foray into obesity

Evan Seigerman, BMO Capital Markets head of healthcare research, joins 'The Exchange' to discuss Pfizer's obesity drug prospects, competitors and much more.

Other symbols: PFE
16 days ago - CNBC Television

Wedbush Ups AAPL Price Target, PFE Acquires MTSR, Morgan Stanley Chip Upgrades

Wedbush continues to see tremendous upside for Apple (AAPL), citing iPhone sales and the new iPhone Air as catalysts. Pfizer's (PFE) acquisition of Metsera (MTSR) sent the obesity drug maker's stock s...

Other symbols: AAPLPFEMS
16 days ago - Schwab Network

Pfizer Jumps Into Weight-Loss Drug Segment With $7.3 Billion Metsera Deal

Metsera (MTSR) shares skyrocketed 60% in premarket trading after Pfizer (PFE) agreed to purchase the biopharma firm for up to $7.3 billion to jump into the lucrative weight-loss drug segment. Shares o...

Other symbols: PFE
16 days ago - Investopedia

Pfizer Tries To Revitalize Obesity Portfolio With $5 Billion Matsera Deal

Pfizer Inc. PFE on Monday agreed to acquire Metsera, Inc. MTSR to accelerate the next generation of medicines for obesity and cardiometabolic diseases.

Other symbols: PFE
16 days ago - Benzinga

Pfizer boosts obesity drug prospects with $7.3 billion deal to buy Metsera

Pfizer said it would acquire weight loss biotech Metsera in a deal valued at up to $7.3 billion, including future payments, as it scrambles to win a slice in the booming obesity drug market.  The move...

Other symbols: PFE
16 days ago - CNBC

Pfizer makes a $4.9 billion bet on obesity drugs with Metsera buyout deal

Metsera's shareholders could see significant bonuses if certain milestones are reached.

Other symbols: PFE
16 days ago - Market Watch

Nasdaq 100 and S&P500: Intel Weakens, Metsera Spikes 59% on Pfizer Deal, Fed in Spotlight

Dow, S&P500 futures pull back today as Metsera pops 59%, Intel drops, and markets question whether Fed policy will match rate cut forecasts.

Other symbols: INTCPFE
16 days ago - FXEmpire

This Anti-Obesity Stock Jumps 60% on $7.3 Billion Bid by Pfizer

Pfizer said it would buy a clinical stage biopharma company for up to $7 billion, as it eyes the lucrative weight-loss drug market currently dominated by Eli Lilly and Novo Nordisk.

Other symbols: PFE
16 days ago - Barrons

Pfizer to Buy Weight-Loss Drug Developer Metsera for Up to $7.3 Billion

Pfizer has agreed to pay up to $7.3 billion for weight-loss drug developer Metsera in a deal that gets the New York drugmaker back into the burgeoning market for obesity drugs.

Other symbols: PFE
16 days ago - WSJ

Pfizer to buy weight-loss drug developer Metsera for up to $4.9 billion

Pfizer said on Monday it would acquire weight-loss drug developer Metsera for up to $4.9 billion to secure its position in the lucrative obesity treatment market.

Other symbols: PFE
16 days ago - Reuters

Pfizer to Acquire Metsera and its Next-Generation Obesity Portfolio

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Metsera, Inc. (NASDAQ: MTSR) today announced the companies have entered into a definitive agreement under which Pfizer will acquire Metsera, a cl...

Other symbols: PFE
16 days ago - Business Wire

Pfizer close to acquiring Metsera for $7.3B, targeting breakthrough obesity drug

Pfizer is making a bold move in the pharmaceutical world by closing in on a $7.3 billion deal to acquire Metsera, a biotech firm focused on next-generation anti-obesity drugs, news platform Financial ...

Other symbols: PFE
17 days ago - Invezz

Pfizer closes in on $7.3 billion takeover of anti-obesity drugmaker Metsera, FT reports

Pfizer is closing in on a potential $7.3 billion takeover of anti-obesity drug developer Metsera , the Financial Times reported on Sunday, citing unidentified sources.

Other symbols: PFE
17 days ago - Reuters

Metsera to Present Research Highlighting its Next-Generation Obesity Portfolio at the 61st EASD Annual Meeting

NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, ...

27 days ago - GlobeNewsWire

Metsera to Present at Upcoming September Investor Conferences

NEW YORK, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) (“Metsera” or the “Company”), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obes...

6 weeks ago - GlobeNewsWire

Metsera Reports Second Quarter 2025 Financial Results and Continued Portfolio Progress

MET-097i (fully biased once-monthly GLP-1 RA) VESPER-1 and interim VESPER-3 data release expected in September 2025; Phase 3 initiation on track for late 2025

2 months ago - GlobeNewsWire

Metsera to Present at Goldman Sachs 46th Annual Global Healthcare Conference

NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) (“Metsera” or the “Company”), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obes...

4 months ago - GlobeNewsWire

Metsera Stock Rises As Company Advances Obesity Pipeline With Encouraging Weight Loss Data

Metsera, Inc. MTSR on Monday released topline data from the Phase 1 clinical trial of MET-233i, an ultra-long-acting amylin analog engineered for class-leading durability, potency and combinability wi...

4 months ago - Benzinga

Metsera rises as experimental weight-loss drug shows promise in small early-stage trial

Shares of weight-loss drug developer Metsera gained as much as 25% on Monday after the company's experimental drug helped patients lose weight in a small, early-stage trial, showing potential for a mo...

4 months ago - Reuters